ESMO–EURACAN Clinical Practice Guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent/metastatic disease

ESMO–EURACAN Clinical Practice Guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent/metastatic disease - European Society For Medical Oncology (ESMO) / European Reference Network on Rare Adult Solid Cancers (EURACAN)

This update refers to Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. P. Bossi, A.T. Chan, L. Licitra et al. Ann Oncol 2021; 32(4): 452-465.

This special article provides updated treatment recommendations for nasopharyngeal carcinoma.

In high-risk locoregionally advanced NPC, the addition of metronomic or standard dose adjuvant capecitabine to CRT improves PFS.

Camrelizumab or toripalimab added to platinum and gemcitabine improves PFS as first-line metastatic treatment in endemic NPC areas.


Read full Guideline